Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaptanib sodium in subfoveal neovascular AMD
NCT00312351Phase 4Terminated
- Sponsor
- OSI Eyetech
- Start
- Apr 2006
- Countries
- 1
01
Overview
A Phase 4 trial of pegaptanib sodium in neovascular age-related macular degeneration (NVAMD), sponsored by OSI Eyetech. Started Apr 2006; status: terminated.
02
Drugs
pegaptanib sodium
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00312351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00312351.